FIG. 7.

Neutralizing antibodies to the adenoviral vector. (A) Neutralizing antibody titers to the adenoviral vector before the first (Pre) and third (pre 3rd) and 2 weeks after the first, second, and third adenoviral vector applications (dose, 2 × 10¹¹ particles) by the tonsillar route (for the immunization regimen, see Fig. 2A). (B) Neutralizing antibody titers to the adenoviral vector were determined before (Pre) and 4 weeks after the first (prime) and second (boost) adenoviral vector applications by the tonsillar (oral; dose, 1 × 10¹¹) or intramuscular (systemic; dose, 6 × 10¹¹) route. The two control macaques receiving Ad-GFP either orally of systemically (for the immunization regimen, see Fig. 3A) were included in the analyses. The means and standard deviations for each group are shown.